Vital organ failure remains common in AL amyloidosis. Solid organ transplantation is
contentious because of the multisystem nature of this disease and risk of recurrence in the …

Therapies for AL amyloidosis have dramatically improved, leading to longer patient survival;
however, more AL amyloidosis patients are reaching end-stage renal disease (ESRD) …

In appropriately selected patients with AL amyloidosis, autologous stem cell transplant
(ASCT) is an established treatment modality with excellent outcomes and decreasing …

Effective systemic therapies suppress toxic light chain production leading to an increased
proportion of patients with light chain (AL) amyloidosis who survive longer albeit with end …

Incidence and outcome of acute renal failure complicating autologous stem cell
transplantation for AL amyloidosis. Background High-dose intravenous melphalan and …

Opinion statement Patients with unexplained heart failure, hepatomegaly, nephrotic
syndrome, or peripheral neuropathy should be evaluated for primary systemic (amyloid …

High‐dose chemotherapy with autologous stem cell transplantation (SCT) is widely used as
a treatment for systemic AL amyloidosis, but its efficacy has not been proved and it has …

We report on a patient with primary AL amyloidosis who presented with progressive liver
failure secondary to hepatic infiltration in the absence of significant extrahepatic …

Patients with hereditary apolipoprotein AI (apoAI) amyloidosis often have extensive visceral
amyloid deposits, and many develop end‐stage renal failure as young adults. Solid organ …

Rationale & Objective Outcomes of kidney transplantation for patients with renal AA
amyloidosis are uncertain, with reports of poor survival and high rates of disease recurrence …